Literature DB >> 20809194

Understanding the relationships between health outcomes in generalized anxiety disorder clinical trials.

Kathleen W Wyrwich1, Neesha Harnam, Julie C Locklear, Henrik Svedsäter, Dennis A Revicki.   

Abstract

BACKGROUND AND AIMS: The Wilson-Cleary health outcomes model is a hypothesized pathway linking traditional clinical variables to health-related quality of life (HRQL). This study tested the application of the Wilson-Cleary model to a patient population with generalized anxiety disorder (GAD) using longitudinal clinical trial data.
METHODS: These secondary analyses pooled data from three similar 8-week, placebo-controlled, double-blind, randomized, multicenter trials of quetiapine XR therapy in GAD. Relevant health assessments for the model concepts included the Clinical Global Impression-Severity of Illness, Hamilton Rating Scale for Anxiety, the Pittsburgh Sleep Quality Index and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form. A lagged path model tested whether the hypothesized relationships at baseline and week 8 between the concepts of the adapted Wilson-Cleary model were consistent with the observed data.
RESULTS: The resulting model fit the data (RMSEA = 0.077; CFI = 0.98; NFI = 0.96) and explained 56% of the variance in overall quality of life assessment at baseline and 69% of the variance in this assessment at week 8. Moderate to strong relationships between the adjacent hypothesized concepts support the specified model.
CONCLUSION: This adapted Wilson-Cleary model for health outcomes validated in GAD should improve the understanding and usefulness of health status measurements in this condition and increase the applications of this model to other clinical trial data.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20809194     DOI: 10.1007/s11136-010-9734-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  44 in total

1.  Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Deborah S Hasin; Frederick S Stinson; Deborah A Dawson; W June Ruan; Risë B Goldstein; Sharon M Smith; Tulshi D Saha; Boji Huang
Journal:  Psychol Med       Date:  2005-10-05       Impact factor: 7.723

2.  Putting Wilson and Cleary to the test: analysis of a HRQOL conceptual model using structural equation modeling.

Authors:  Karen H Sousa; Oi-Man Kwok
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

3.  Does generalized anxiety disorder predict coronary heart disease risk factors independently of major depressive disorder?

Authors:  Steven D Barger; Sumner J Sydeman
Journal:  J Affect Disord       Date:  2005-09       Impact factor: 4.839

4.  Generalized anxiety disorder and clinical worry episodes in young women.

Authors:  J Hoyer; E S Becker; J Margraf
Journal:  Psychol Med       Date:  2002-10       Impact factor: 7.723

5.  Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma.

Authors:  L Wettergren; M Björkholm; U Axdorph; A Langius-Eklöf
Journal:  Qual Life Res       Date:  2004-10       Impact factor: 4.147

6.  The association of health-related quality of life with survival among persons with HIV infection in the United States.

Authors:  William E Cunningham; Stephen Crystal; Samuel Bozzette; Ron D Hays
Journal:  J Gen Intern Med       Date:  2005-01       Impact factor: 5.128

7.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

8.  Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies.

Authors:  Jean Endicott; James M Russell; Joel Raskin; Michael J Detke; Janelle Erickson; Susan G Ball; Martin Marciniak; Ralph W Swindle
Journal:  J Clin Psychiatry       Date:  2007-04       Impact factor: 4.384

9.  Health-related quality of life and utilities in primary-care patients with generalized anxiety disorder.

Authors:  Dennis A Revicki; Nancy Brandenburg; Louis Matza; Mark C Hornbrook; David Feeny
Journal:  Qual Life Res       Date:  2008-10-23       Impact factor: 4.147

10.  Quality of life can both influence and be an outcome of general health perceptions after heart surgery.

Authors:  Lars Mathisen; Marit H Andersen; Marijke Veenstra; Astrid K Wahl; Berit R Hanestad; Erik Fosse
Journal:  Health Qual Life Outcomes       Date:  2007-05-24       Impact factor: 3.186

View more
  5 in total

1.  Functional status, life-space mobility, and quality of life: a longitudinal mediation analysis.

Authors:  John P Bentley; Cynthia J Brown; Gerald McGwin; Patricia Sawyer; Richard M Allman; David L Roth
Journal:  Qual Life Res       Date:  2012-11-17       Impact factor: 4.147

Review 2.  The impact of medication on health-related quality of life in patients with generalized anxiety disorder.

Authors:  Hilary Wilson; Sally Mannix; Hafiz Oko-osi; Dennis A Revicki
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 3.  A history of health-related quality of life outcomes in psychiatry.

Authors:  Dennis A Revicki; Leah Kleinman; David Cella
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

4.  Application of a health-related quality of life conceptual model in community-dwelling older Chinese people with diabetes to understand the relationships among clinical and psychological outcomes.

Authors:  Ann Tak Ying Shiu; Kai Chow Choi; Diana Tze Fan Lee; Doris Sau Fung Yu; Wai Man Ng
Journal:  J Diabetes Investig       Date:  2014-02-11       Impact factor: 4.232

Review 5.  A systematic review of the application of Wilson and Cleary health-related quality of life model in chronic diseases.

Authors:  Adedokun Oluwafemi Ojelabi; Yitka Graham; Catherine Haighton; Jonathan Ling
Journal:  Health Qual Life Outcomes       Date:  2017-12-11       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.